id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2017-0003-0014,DEA,DEA-2017-0003,Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)]in Schedule II,Rule,,2017-11-22T05:00:00Z,2017,11,,,2017-11-22T13:21:09Z,2017-25275,0,0,0900006482c9ed02
DEA-2017-0003-0002,DEA,DEA-2017-0003,Dronabinol 8 factor_,Supporting & Related Material,,2017-03-23T04:00:00Z,2017,3,,,2017-03-23T13:26:47Z,,0,0,090000648252013e
DEA-2017-0003-0003,DEA,DEA-2017-0003,HHS Syndros recommendation,Supporting & Related Material,,2017-03-23T04:00:00Z,2017,3,,,2017-03-23T13:28:39Z,,0,0,0900006482520140
DEA-2017-0003-0001,DEA,DEA-2017-0003,Schedules of Controlled Substances: Placement of FDA-Approved Products of Oral Solutions Containing Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)]in Schedule II,Rule,,2017-03-23T04:00:00Z,2017,3,2017-03-23T04:00:00Z,2017-04-25T03:59:59Z,2017-04-25T13:02:33Z,2017-05809,0,0,090000648251f9ee